Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Yusuke Watanabe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3489-3180; OpenAlex author ID A5027923975. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 9

  1. Clinical efficacy of pancreas-preserving distal pancreatectomy for the treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2024.108958↗
  2. Conversion surgery for initially unresectable locally advanced pancreatic ductal adenocarcinoma after chemotherapy followed by carbon-ion radiotherapy: a case … Co-author DOI 10.1186/s13256-023-04311-3↗
  3. Extensive (subtotal) distal pancreatectomy for pancreatic ductal adenocarcinoma: a propensity score matched cohort study of short- and long-term outcomes compa… Co-author DOI 10.1007/s00423-022-02453-4↗
  4. FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience. Co-author DOI 10.1007/s00595-020-02123-2↗
  5. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study. Co-author DOI 10.1007/s00423-019-01754-5↗
  6. Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma in Elderly Patients: Special Reference to Postoperative Adjuvant Chemotherapy. Co-author DOI 10.1007/s00268-018-4496-y↗
  7. Effect of postoperative major complications on prognosis after pancreatectomy for pancreatic cancer: a retrospective review. Co-author DOI 10.1007/s00595-016-1426-1↗
  8. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000258↗
  9. Predictors and Diagnostic Strategies for Early-Stage Pancreatic Ductal Adenocarcinoma: A Retrospective Study. Co-author DOI 10.1097/mpa.0000000000000393↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kohei Nakata · 3 shared papers, 2021–2025 · strength 0.52
  2. Naoki Ikenaga · 3 shared papers, 2021–2025 · strength 0.52
  3. Noboru Ideno · 4 shared papers, 2015–2025 · strength 0.48
  4. Kazuyoshi Nishihara · 4 shared papers, 2017–2024 · strength 0.48
  5. Takao Ohtsuka · 5 shared papers, 2015–2022 · strength 0.45
  6. Toru Nakano · 3 shared papers, 2017–2024 · strength 0.41
  7. Masafumi Nakamura · 2 shared papers, 2022–2025 · strength 0.40
  8. Tomohiko Shinkawa · 2 shared papers, 2018–2024 · strength 0.33
  9. Yasuhisa Mori · 2 shared papers, 2021–2022 · strength 0.29
  10. Kousei Ishigami · 1 shared paper, 2025 · strength 0.23
  11. Nobuhiro Fujita · 1 shared paper, 2025 · strength 0.23
  12. Masatoshi Murakami · 1 shared paper, 2025 · strength 0.23
  13. Toshiya Abe · 1 shared paper, 2025 · strength 0.23
  14. Nao Fujimori · 1 shared paper, 2025 · strength 0.23
  15. Yoshihiro Ogawa · 1 shared paper, 2025 · strength 0.23
  16. Kenjiro Date · 1 shared paper, 2024 · strength 0.23
  17. Masafumi Nakamura · 2 shared papers, 2019–2021 · strength 0.19
  18. Kenoki Ohuchida · 2 shared papers, 2015–2021 · strength 0.16
  19. Taketo Matsunaga · 3 shared papers, 2015–2019 · strength 0.15
  20. Yoshihiro Miyasaka · 3 shared papers, 2015–2019 · strength 0.15
  21. Ryuichiro Kimura · 1 shared paper, 2021 · strength 0.12
  22. Atsushi Fujii · 1 shared paper, 2021 · strength 0.12
  23. Koji Shindo · 1 shared paper, 2021 · strength 0.12
  24. Sho Endo · 1 shared paper, 2018 · strength 0.10
  25. Sokichi Matsumoto · 1 shared paper, 2017 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.